The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Next Generation Sequencing (NGS) Market, 2020-2030: Service Providers (Whole Genome, Whole Exome and Targeted Sequencing) and Technology Platforms [COVID-19 Series]

  • Lowest Price Guaranteed From USD 4,499

  • Published
    December 2019

  • Pages
    381

  • View Count
    4565

Example Insights

Next Generation Sequencing (NGS) Market, 2019-2030-Context Next Generation Sequencing (NGS) Market, 2019-2030-Service Providers Next Generation Sequencing (NGS) Market, 2019-2030-list of Genome Sequencing system Next Generation Sequencing (NGS) Market, 2019-2030-Market Characterized
Next Generation Sequencing (NGS) Market, 2019-2030-Clinical Trial Analysis Next Generation Sequencing (NGS) Market, 2019-2030-Patent Analysis Next Generation Sequencing (NGS) Market, 2019-2030-Capability Benchmarking Next Generation Sequencing (NGS) Market, 2019-2030-Various Therapeutic Areas
Next Generation Sequencing (NGS) Market, 2019-2030-Market Forecast Next Generation Sequencing (NGS) Market, 2019-2030-Futuer Forecast    

 

Overview

[COVID-19 SERIES] Advances in DNA sequencing technologies have led to significant developments in a variety of healthcare-focused research fields, such as precision medicine and diagnostics. Particularly, the impact of next generation sequencing (NGS) methods, enabling whole genome and whole exome sequencing, has been the most profound. This high throughput, parallel genome sequencing technology has greatly reduced the overall cost and time investment. In fact, compared to the Human Genome Project (~USD 3 billion), the cost of sequencing a single genome has decreased to USD 1,000, using currently available technologies. Owing to the ongoing innovation in this field, stakeholders believe that the aforementioned cost may get further reduced to USD 100 over the next decade.  This decrease in genome sequencing costs has led to a marked increase in the number of genomes being sequenced around the world. In fact, several large scale efforts, such as UK Biobank and GenomeAsia 100k, have been initiated in order to collect genomic data for use in medical research. Big pharma players, including AstraZeneca, GSK, Pfizer, Merck and Roche, are actively on the lookout for collaborating with such data repositories in order to access the aforementioned information. 

Despite the progress made in this field of research, there are several existing challenges related to the NGS process affiliated workflow and data analysis. The lack of versatile in silico tools is considered to be the major rate-limiting step in NGS data analysis and interpretations. At present, industry stakeholders are actively collaborating in order to integrate their respective resources for mining these large and complex datasets to generate clinically relevant, actionable insights. Additionally, there is a need for better genomic library preparation protocols, which required less starting material, and are capable of generating libraries with more precisely estimated insert sizes and longer reads at reduced error rates. More efficient genome assembly algorithms and better processors (increased computational power) for genomic data processing are also likely to get developed. We are led to believe that, once the aforementioned challenges are addressed, this segment of the biopharmaceutical industry will witness significant growth.

Scope of the Report

The ‘Next Generation Sequencing (NGS) Market, 2020-2030: Service Providers (Whole Genome, Whole Exome and Targeted Sequencing) and Technology Platforms’ report features an extensive study of the current landscape and the future opportunities associated with service / technologies providers. Amongst other elements, the report features:

  • An overview of the genome sequencing service providers landscape, featuring information on year of establishment, company size, geographical location and types of services offered (sanger sequencing, genotyping, whole genome sequencing, whole exome sequencing targeted sequencing and bioinformatics). Further, it provides details on the cost of services, sequencing systems used, average turn-around time and sequencing coverage, for certain types of sequencing-related services (whole genome, whole exome and targeted sequencing) offered by contract service providers.
  • An overview of genome sequencing technologies landscape, featuring information on type of applications, run time, maximum reads per run, maximum sequencing output, maximum read length, type of sequencing technique, quality score and cost. It also provides information on the technology providers involved in this domain, including information on year of establishment, company size and geographical location. 
  • An informed competitiveness analysis of the genome sequencing technologies captured in our database, taking into consideration relevant parameters, such as supplier power (based on company size of technology provider) and other important technology-related specifications, such as types of applications, maximum sequencing output, maximum reads per run, maximum read length, quality score and cost of sequencer.
  • An in-depth analysis of intellectual property related to this field of research, in order to generate an opinion on how the industry has evolved from the R&D perspective. The analysis takes into consideration genome sequencing-related patents that have been filed / granted since 2015, highlighting publication year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players, patent characteristics and geography.
  • An analysis of completed, ongoing and planned clinical studies related to genome sequencing, featuring details on registration year, type of sponsors / collaborators, current status of trials, type of study design, target therapeutic area, type of application, regional distribution of clinical trials and enrolled patient population.
  • An analysis of the various genome sequencing-focused initiatives of the ten big pharma players (shortlisted based on extent of activity in genome sequencing domain), highlighting the key focus areas of such companies along with information on funding, collaboration and acquisition activity.
  • A case study on the various national and international, government sponsored initiatives related to genome sequencing, analyzed on the basis of year of initiation, type of investors, type of participant organization, research objectives, geographical distribution, region-specific data access policies and key focus areas of research.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the genome sequencing services and technologies market. Based on several parameters, such as number of genomes sequenced annually, average cost of sequencing, revenues generated by major players and expected annual growth rate, we have provided an informed estimate of the likely evolution of the market, for the period 2020-2030. The chapter also presents a detailed segmentation of the aforementioned opportunity across [A] key application areas (diagnostics, drug discovery, precision medicine and others), [B] end-users (hospitals and clinics, academics and research institutes, pharmaceuticals companies and others), [C] types of technologies (sequencing by synthesis, ion semiconductor, single-molecule real-time sequencing, nanopore and others), [D] types of services (whole genome sequencing, whole exome sequencing and targeted sequencing) and [E] key geographical regions (North America, Asia-Pacific, Europe, and rest of the world).

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

  • Michael Powell (Chief Scientific Officer, DiaCarta)
  • Mike Klein (Chief Executive Officer, Genomenon) 

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the genome sequencing services and technology providers market in the mid to long term.

Chapter 3 provides a general overview of the concept of genome sequencing with information on its process workflow, types including whole genome, whole exome and targeted sequencing, epigenetics, metagenomics and RNA sequencing and a wide array of uses in clinical research. It further highlights the history and evolution of genome sequencing with details on first, second and third generation NGS platforms, and a brief outline of various applications of genome sequencing including cancer and biomarker research, precision medicine, diagnostics and forensics research. Further, it includes a discussion on the various limitations / constraints and future perspectives of this evolving segment of pharmaceutical industry.

Chapter 4 provides an overview of genome sequencing service providers landscape, featuring information on year of establishment, company size, geographical location and types of services offered (sanger sequencing, genotyping, whole genome sequencing, whole exome sequencing targeted sequencing and bioinformatics). Further, it provides details on the cost of services, sequencing systems used, average turn-around time and sequencing coverage, for certain types of sequencing-related services (whole genome, whole exome and targeted sequencing) offered by contract service providers.

Chapter 5 provides an overview of genome sequencing technologies landscape, featuring information on the type of applications, run time, maximum reads per run, maximum sequencing output, maximum read length, type of sequencing technique, quality score and cost. It also provides information on the technology providers involved in this domain, including information on year of establishment, company size and geographical location. 

Chapter 6 provides an informed competitiveness analysis of the genome sequencing technologies captured in our database, taking into consideration relevant parameters, such as supplier power (based on company size of technology provider) and other important technology-related specifications, such as types of applications, maximum sequencing output, maximum reads per run, maximum read length, quality score and cost of sequencer.

Chapter 7 includes brief profiles of prominent service providers engaged in this domain. Each profile provides a brief overview of the company, its financial information (if available), a detailed description of services offered, recent developments and an informed future outlook.

Chapter 8 includes brief profiles of prominent technology developers engaged in this domain, featuring an overview of the company, its financial information (if available), a detailed description of its proprietary technology platform(s), recent developments and an informed future outlook.

Chapter 9 provides an in-depth patent analysis to provide an overview on how the industry has evolved from the R&D perspective. For this analysis, we looked at the patents related to genome sequencing that have been published since 2015. The analysis also highlights key information associated with these patents, including publication year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players, patent characteristics and geography.

Chapter 10 provides an analysis of completed, ongoing and planned clinical studies related to genome sequencing. The trials were analyzed on the basis of various relevant parameters, such as on registration year, type of sponsors / collaborators, current status of trials, type of study design, target therapeutic area, type of application, regional distribution of clinical trials and enrolled patient population.

Chapter 11 presents an analysis of the various genome sequencing-focused initiatives of ten big pharma players (out of top 20 established pharmaceutical players), highlighting the key focus areas of such companies along with information on funding, collaboration and acquisition activity.

Chapter 12 presents a case study on various national and international government sponsored initiatives related to genome sequencing, analyzed on the basis of year of initiation, type of investors, type of participant organization, research objectives, geographical distribution, region-specific data access policies and key focus areas of research.

Chapter 13 presents a detailed market forecast, highlighting the future potential of the genome sequencing services and technology market till the year 2030. The chapter features the likely distribution of the opportunity across [A] application areas (diagnostics, drug discovery, precision medicine and others), [B] end-users (hospitals and clinics, academics and research institutes, pharmaceuticals companies and others), [C] types of technologies (sequencing by synthesis, ion semiconductor, single-molecule real-time sequencing, nanopore and others), [D] types of services (whole genome sequencing, whole exome sequencing and targeted sequencing) and [E] key geographical regions (North America, Asia-Pacific, Europe, and rest of the world).

Chapter 14 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Genome Sequencing
3.3. Types of Genome Sequencing
3.4. History and Evolution of Genome Sequencing
3.4.1. First Generation DNA Sequencers
3.4.2. High Throughput-Next Generation Sequencing (HT-NGS)
3.4.2.1. Second Generation HT-NGS Platforms
3.4.2.2. Third Generation HT-NGS Platforms
3.4.2.2.1. Heliscope™ Single Molecule Sequencer
3.4.2.2.2. Single Molecule Real Time (SMRT™) Sequencer
3.4.2.2.3. Single Molecule Real Time (RNAP) Sequencer
3.4.2.2.4. Nanopore DNA Sequencer
3.4.2.2.5. Multiplex Polony Technology
3.4.2.2.6. The Ion Torrent Sequencing Technology

3.5. Practical Relevance of Genome Sequencing
3.5.1. Identification of Single Nucleotide Variants
3.5.2. Identification of Large Structural Variants
3.5.3. Variant Quality Control and Genotype Validation
3.5.4. Haplotype Phasing

3.5.3. Comparison of Available Genome Sequencing Technologies

3.6. Applications of Genome Sequencing
3.6.1. Cancer and Affiliated Biomarker Research
3.6.2. Diagnostics
3.6.3. Personalized / Precision Medicine
3.6.4. Forensics

3.7. Challenges Associated with Genome Sequencing
3.8. Future Perspectives

4. GENOME SEQUENCING SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Genome Sequencing Service Providers: Market Landscape of Industry
 Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geographical Location
4.2.4. Analysis by Type of Services Offered
4.2.4.1. Whole Genome Sequencing Services
4.2.4.2. Whole Exome Sequencing Services
4.2.4.3. Targeted Sequencing Services

4.3. Genome Sequencing Service Providers: Market Landscape of Non-Industry Players
Industry Players 
4.3.1. Analysis by Year of Establishment
4.3.3. Analysis by Geographical Location
4.3.4. Analysis by Type of Services
4.3.4.1. Whole Genome Sequencing Services
4.3.4.2. Whole Exome Sequencing Services
4.3.4.3. Targeted Sequencing Services

5. GENOME SEQUENCING TECHNOLOGIES: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Genome Sequencing Technologies: Overall Market Landscape
5.2.1. Analysis by Type of Application
5.2.2. Analysis by Maximum Sequencing Output
5.2.3. Analysis by Maximum Reads per Run
5.2.4. Analysis by Type of Sequencing Technique
5.2.5. Analysis of Technology Providers by Year of Establishment
5.2.6. Analysis of Technology Providers by Company Size
5.2.7. Analysis of Technology Providers by Geographical Location

6. PLATFORM COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.2.1. Platform Competitiveness Analysis: Peer Group I
6.2.2. Platform Competitiveness Analysis: Peer Group II
6.2.3. Platform Competitiveness Analysis: Peer Group III
6.2.4. Platform Competitiveness Analysis: Peer Group IV

7. COMPANY PROFILES: GENOME SEQUENCING SERVICE PROVIDERS
7.1. Chapter Overview
7.2. Admera Health
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. Applied Biological Materials
7.3.1. Company Overview
7.3.2. Services Portfolio
7.3.3. Recent Developments and Future Outlook

7.4. BGI Genomics
7.4.1. Company Overview
7.4.2. Services Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. CD Genomics
7.5.1. Company Overview
7.5.2. Services Portfolio
7.5.3. Recent Developments and Future Outlook

7.6. DNA Link
7.6.1. Company Overview
7.6.2. Services Portfolio
7.6.3. Recent Developments and Future Outlook

7.7. Eurofins Genomics (Eurofins Scientific)
7.7.1. Company Overview
7.7.2. Services Portfolio
7.7.3. Recent Developments and Future Outlook

7.8. Fulgent Genetics
7.8.1. Company Overview
7.8.2. Services Portfolio
7.8.3. Recent Developments and Future Outlook

7.9. Gene by Gene
7.9.1. Company Overview
7.9.2. Services Portfolio
7.9.3. Recent Developments and Future Outlook

7.10. GENEWIZ
7.10.1. Company Overview
7.10.2. Services Portfolio
7.10.3. Recent Developments and Future Outlook

7.11. MedGenome
7.11.1. Company Overview
7.11.2. Services Portfolio
7.11.3. Recent Developments and Future Outlook

7.12. Novogene
7.12.1. Company Overview
7.12.2. Services Portfolio
7.12.3. Recent Developments and Future Outlook

7.13. Omega Biosciences
7.13.1. Company Overview
7.13.2. Services Portfolio
7.13.3. Recent Developments and Future Outlook

7.14. Psomagen
7.14.1. Company Overview
7.14.2. Services Portfolio
7.14.3. Recent Developments and Future Outlook

7.15. Veritas Genetics
7.15.1. Company Overview
7.15.2. Services Portfolio
7.15.3. Recent Developments and Future Outlook

7.16. Xcerlis Labs
7.16.1. Company Overview
7.16.2. Services Portfolio
7.16.3. Recent Developments and Future Outlook

8. COMPANY PROFILES: GENOME SEQUENCING TECHNOLOGY PROVIDERS
8.1. Chapter Overview

8.2. Illumina
8.2.1. Company Overview
8.2.2. Financial Information
8.2.3. Product Portfolio
8.2.3.1. iSeq 100™ System
8.2.3.2. MiniSeq™ System
8.2.3.3. MiSeq® System
8.2.3.4. NextSeq® Series
8.2.3.5. NextSeq 6000® System
8.2.4. Recent Developments and Future Outlook

8.3. Oxford Nanopore Technologies
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Product Portfolio
8.3.3.1. MinION™ System
8.3.3.2. GridION™ System
8.3.3.3. PromethION™ System
8.3.4. Recent Developments and Future Outlook

8.4. Thermo Fisher Scientific
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Product Portfolio
8.4.3.1. Ion S5™ Systems
8.4.3.2. Ion GeneStudio S5™ System
8.4.3.3. SeqStudio™ System
8.4.3.4. Applied Biosystems® 3500 System
8.4.3.5. Ion PGM™ System
8.4.3.6. Ion Proton™ System
8.4.4. Recent Developments and Future Outlook

9. PATENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology

9.3. Genome Sequencing: Analysis of Patent Portfolio
9.3.1. Analysis by Publication Year
9.3.2. Analysis by Issuing Authority / Patent Offices Involved
9.3.3. Analysis by CPC Symbols
9.4. Emerging Focus Areas
9.5. Leading Players: Analysis by Number of Patents

9.6. Genome Sequencing: Patent Benchmarking Analysis
9.6.1. Analysis by Patent Characteristics
9.6.2. Analysis by Geography
9.7. Patent Valuation Analysis

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Genome Sequencing: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Registration Year and Geography
10.3.3. Analysis by Type of Sponsors / Collaborators
10.3.4. Analysis by Trial Status
10.3.5. Analysis by Trial Phase
10.3.6. Analysis by Type of Study Design
10.3.7. Analysis by Target Therapeutic Area
10.3.8. Analysis by Type of Application
10.3.10. Analysis by Target Therapeutic Area and Type of Application
10.3.11. Analysis by Number of Trials and Geography
10.3.12. Analysis by Enrolled Patient Population and Geography
10.3.13. Analysis by Number of Trials, Trial Status and Geography
10.3.14. Analysis by Enrolled Patient Population, Trial Status and Geography

11. GENOME SEQUENCING RELATED INITIATIVES OF BIG PHARMA PLAYERS
11.1. Chapter Overview
11.2. Scope and Methodology
11.2.1. Analysis by Type of Initiative
11.2.2. Analysis by Type of Collaboration
11.2.3. Analysis by Focus Area
11.2.4. Leading Players: Analysis by Number of Initiatives

12. CASE STUDY: GOVERNMENT SPONSORED INITIATIVES
12.1. Chapter Overview
12.2. Government Sponsored Initiatives
12.2.1. Analysis by Study Status
12.2.2. Analysis by Study Start Year
12.2.3. Analysis by Geographical Scope
12.2.4. Analysis of National Initiatives by Geographical Location, Year and Number of Genomes Sequenced
12.2.5. Analysis by Research Objective
12.2.6. Analysis by Focus Area
12.2.7. Analysis by Type of Players
12.2.8. Analysis by Type of Investors
12.2.9. Analysis by Region-specific Data Accessibility

13. MARKET FORECAST
13.1. Chapter Overview
13.2. Overall Next Generation Sequencing Market, 2020-2030
13.3. Next Generation Sequencing Market: Distribution across Key Market Segments, 2020-2030
13.3.1. Genome Sequencing Products Market: Distribution by Type of Technology,2020 and 2030
13.3.2. Genome Sequencing Services Market: Distribution by Type of Service, 2020 and 2030
13.4. Next Generation Sequencing Market: Distribution by Application Area, 2020 and 2030
13.5. Next Generation Sequencing Market: Distribution by End-Users, 2020 and 2030
13.6. Next Generation Sequencing Market: Distribution by Geographical Regions, 2020 and 2030

13.6.1. Next Generation Sequencing Market in North America, 2020-2030
13.6.1.1. Next Generation Sequencing Market in North America: Distribution by Application Area, 2020-2030
13.6.1.1.1. Next Generation Sequencing Market for Diagnostics in North America, 2020-2030
13.6.1.1.2. Next Generation Sequencing Market for Drug Discovery in North America, 2020-2030
13.6.1.1.3. Next Generation Sequencing Market in for Precision Medicine in North America, 2020-2030
13.6.1.1.4. Next Generation Sequencing Market in for Other Application Areas in North America, 2020-2030
13.6.1.2. Next Generation Sequencing Market in North America: Distribution by End-Users,2020-2030

13.6.1.2.1. Next Generation Sequencing Market for Hospitals and Clinics in North America, 2020-2030
13.6.1.2.2. Next Generation Sequencing Market for Academic and Research Institutes in North America, 2020-2030
13.6.1.2.3. Next Generation Sequencing Market for Pharmaceutical Companies in North America, 2020-2030
13.6.1.2.4. Next Generation Sequencing Market for Other Users in North America, 2020-2030

13.6.2. Next Generation Sequencing Market in Europe, 2020-2030
13.6.2.1. Next Generation Sequencing Market in Europe: Distribution by Application Area, 2020-2030
13.6.2.1.1. Next Generation Sequencing Market for Diagnostics in Europe, 2020-2030
13.6.2.1.2. Next Generation Sequencing Market for Drug Discovery in Europe, 2020-2030
13.6.2.1.3. Next Generation Sequencing Market for Precision Medicine in Europe, 2020-2030
13.6.2.1.4. Next Generation Sequencing Market in for Other Application Areas in Europe, 2020-2030
13.6.2.2. Next Generation Sequencing Market in Europe: Distribution by End-Users, 2020-2030 
13.6.2.2.1. Next Generation Sequencing Market for Hospitals and Clinics in Europe, 2020- 2030
13.6.2.2.2. Next Generation Sequencing Market for Academic and Research Institutes in Europe, 2020-2030
13.6.2.2.3. Next Generation Sequencing Market for Pharmaceutical Companies in Europe, 2020-2030
13.6.2.2.4. Next Generation Sequencing Market for Other Users in Europe, 2020-2030

13.6.3. Next Generation Sequencing Market in Asia-Pacific, 2020-2030
13.6.3.1. Next Generation Sequencing Market in Asia-Pacific: Distribution by Application Area, 2020-2030
13.6.3.1.1. Next Generation Sequencing Market for Diagnostics in Asia-Pacific, 2020-2030
13.6.3.1.2. Next Generation Sequencing Market for Drug Discovery in Asia-Pacific, 2020-2030
13.6.3.1.3. Next Generation Sequencing Market for Precision Medicine in Asia-Pacific, 2020-2030
13.6.3.1.4. Next Generation Sequencing Market for Other Application Areas in Asia-Pacific, 2020-2030
13.6.3.2. Next Generation Sequencing Market in Asia-Pacific: Distribution by End-Users 2020-2030
13.6.3.2.1. Next Generation Sequencing Market for Hospitals and Clinics in Asia-Pacific, 2020-2030
13.6.3.2.2. Next Generation Sequencing Market for Academic and Research Institutes in Asia-Pacific, 2020-2030
13.6.3.2.3. Next Generation Sequencing Market for Pharmaceutical Companies in Asia-Pacific, 2020-2030
13.6.3.2.4. Next Generation Sequencing Market for Other Users in Asia-Pacific, 2020-2030

13.6.4. Next Generation Sequencing Market in Rest of the World, 2020-2030
13.6.4.1. Next Generation Sequencing Market in Rest of the World: Distribution by Application Area, 2020-2030
13.6.4.1.1. Next Generation Sequencing Market for Diagnostics in Rest of the World, 2020-2030
13.6.4.1.2. Next Generation Sequencing Market for Drug Discovery in Rest of the World, 2020-2030
13.6.4.1.3. Next Generation Sequencing Market for Precision Medicine in Rest of the World, 2020-2030
13.6.4.1.4. Next Generation Sequencing Market for Other Application Areas in Rest of the World, 2020-2030
13.6.4.2. Next Generation Sequencing Market in Rest of the World: Distribution by End-Users, 2020-2030
13.6.4.2.1. Next Generation Sequencing Market for Hospitals and Clinics in Rest of the World, 2020-2030
13.6.4.2.2. Next Generation Sequencing Market for Academic and Research Institutes in Rest of the World, 2020-2030
13.6.4.2.3. Next Generation Sequencing Market for Pharmaceutical Companies in Rest of the World, 2020-2030
13.6.4.2.4. Next Generation Sequencing Market for Other Users in Rest of the World, 2020-2030

14. FUTURE OPPORTUNITIES

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 3.1 Steps Involved in Genome Sequencing
Figure 3.2 Types of Genome Sequencing
Figure 3.3 Types of Third Generation Sequencing Technologies
Figure 3.4 Applications of Genome Sequencing
Figure 4.1 Genome Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
Figure 4.2 Genome Sequencing Service Providers (Industry Players): Distribution by Company Size
Figure 4.3 Genome Sequencing Service Providers (Industry Players): Distribution by Geography
Figure 4.4 Genome Sequencing Service Providers (Industry Players): Distribution by Type of Services Offered
Figure 4.5 Whole Genome Sequencing Services (Industry Players): Distribution by Technology Used
Figure 4.6 Whole Exome Sequencing Services (Industry Players): Distribution by Technology Used
Figure 4.7 Targeted Sequencing Services (Industry Players): Distribution by Technology Used
Figure 4.8 Genome Sequencing Service Providers (Non-Industry Players): Distribution by Year of Establishment
Figure 4.9 Genome Sequencing Service Providers (Non-Industry Players): Distribution by Geography
Figure 4.10 Genome Sequencing Service Providers (Non-Industry Players): Distribution by Type of Services Offered
Figure 4.11 Whole Genome Sequencing Services (Non-Industry Players): Distribution by Technology Used
Figure 4.12 Whole Exome Sequencing Services (Non-Industry Players): Distribution by Technology Used
Figure 4.13 Targeted Sequencing Services (Non-Industry Players): Distribution by Technology Used
Figure 5.1 Genome Sequencing Technologies: Distribution by Type of Application
Figure 5.2 Genome Sequencing Technologies: Distribution by Maximum Sequencing Output
Figure 5.3 Genome Sequencing Technologies: Distribution by Maximum Reads per Run
Figure 5.4 Genome Sequencing Technologies: Distribution by Sequencing Technique
Figure 5.5 Genome Sequencing Technology Providers: Distribution by Year of Establishment
Figure 5.6 Genome Sequencing Technology Providers: Distribution by Company Size
Figure 5.7 Genome Sequencing Technology Providers: Distribution by Geography
Figure 6.1 Platform Competitiveness Analysis: Peer Group I
Figure 6.2 Platform Competitiveness Analysis: Peer Group II
Figure 6.3 Platform Competitiveness Analysis: Peer Group III
Figure 6.4 Platform Competitiveness Analysis: Peer Group IV
Figure 8.1 Illumina: Annual Revenues, 2013- Q32020 (USD Million)
Figure 8.2 Illumina: Product Portfolio
Figure 8.3 Oxford Nanopore Technologies: Product Portfolio
Figure 8.4 Thermo Fisher Scientific: Annual Revenues, 2013-Q32020 (USD Million)
Figure 8.5 Thermo Fisher Scientific: Product Portfolio
Figure 9.1 Patent Portfolio: Distribution by Type of Patent
Figure 9.2 Patent Portfolio: Cumulative Distribution by Publication Year
Figure 9.4 Patent Portfolio: Distribution by Geographical Region
Figure 9.5 Patent Portfolio: Distribution by CPC Symbols
Figure 9.6 Patent Portfolio: Emerging Focus Areas
Figure 9.7 Leading Players: Distribution by Size of Patent Portfolio
Figure 9.8 Patent Portfolio: Benchmarking by Patent Characteristics
Figure 9.9 Patent Portfolio: Benchmarking by International Patents
Figure 9.10 Patent Portfolio: Distribution by Geography and Type of Patent
Figure 9.11 Patent Portfolio: Distribution by Patent Age
Figure 9.12 Patent Portfolio: Valuation Analysis
Figure 10.1 Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Trial Registration Year
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Figure 10.3 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Study Start Year
Figure 10.4 Clinical Trial Analysis: Distribution by Type of Sponsors / Collaborators
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.6 Clinical Trial Analysis: Distribution by Type of Study Design
Figure 10.7 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 10.8 Clinical Trial Analysis: Distribution by Type of Application
Figure 10.9 Clinical Trial Analysis: Distribution by Target Therapeutic Area and Type of Application
Figure 10. 10 Clinical Trial Analysis: Distribution by Number of Trials and Geography
Figure 10.11 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Geography
Figure 10.12 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
Figure 10.13 Clinical Trial Analysis: Distribution by Enrollment Patient Population, Trial Status and Geography
Figure 11.1 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 11.2 Big Pharma Initiatives: Heat Map Analysis based on Type of Initiative
Figure 11.3 Big Pharma Initiatives: Distribution by Type of Collaboration
Figure 11.4 Big Pharma Initiatives: Heat Map Analysis based on Type of Collaboration
Figure 11.5 Big Pharma Initiatives: Distribution by Focus Area
Figure 11.6 Big Pharma Initiatives: Heat Map Analysis based on Focus Area
Figure 11.7 Leading Players: Distribution by Number of Initiatives
Figure 12.1 Government Sponsored Initiatives: Distribution by Study Status
Figure 12.2 Government Sponsored Initiatives: Distribution by Study Start Year
Figure 12.3 Government Sponsored Initiatives: Distribution by Geographical Scope
Figure 12.4 World Map Analysis of National Initiatives by Geographical Location, Year and Number of Genomes Sequenced
Figure 12.5 Government Sponsored Initiatives: Distribution by Research Objective
Figure 12.6 Government Sponsored Initiatives: Distribution by Focus Area
Figure 12.7 Government Sponsored Initiatives: Distribution by Type of Players
Figure 12.8 Government Sponsored Initiatives: Distribution by Type of Investors
Figure 13.1 Overall Next Generation Sequencing Market, 2020-2030 (USD Billion)
Figure 13.2 Next Generation Sequencing Market: Distribution by Key Market Segments, 2020-2030 (USD Billion)
Figure 13.3 Genome Sequencing Products Market: Distribution by Type of Technology, 2020 and 2030 (USD Billion)
Figure 13.4 Genome Sequencing Services Market: Distribution by Type of Service, 2020 and 2030 (USD Billion)
Figure 13.5 Next Generation Sequencing Market: Distribution by Application Area, 2020 and 2030 (USD Billion)
Figure 13.6 Next Generation Sequencing Market: Distribution by End-Users, 2020 and 2030 (USD Billion)
Figure 13.7 Next Generation Sequencing Market: Distribution by Geographical Regions, 2020 and 2030 (USD Billion)
Figure 13.8 Next Generation Sequencing Market in North America, 2020-2030 (USD Billion)
Figure 13.9 Next Generation Sequencing Market in North America: Distribution by Application Area, 2020-2030 (USD Billion)
Figure 13.10 Next Generation Sequencing Market for Diagnostics in North America, 2020-2030 (USD Billion)
Figure 13.11 Next Generation Sequencing Market for Drug Discovery in North America, 2020-2030 (USD Billion)
Figure 13.12 Next Generation Sequencing Market in for Precision Medicine in North America, 2020-2030 (USD Billion)
Figure 13.13 Next Generation Sequencing Market in for Other Application Areas in North America, 2020-2030 (USD Billion)
Figure 13.14 Next Generation Sequencing Market in North America: Distribution by End-Users, 2020-2030 (USD Billion)
Figure 13.15 Next Generation Sequencing Market for Hospitals and Clinics in North America, 2020-2030 (USD Billion)
Figure 13.16 Next Generation Sequencing Market for Academic and Research Institutes in North America, 2020-2030 (USD Billion)
Figure 13.17 Next Generation Sequencing Market for Pharmaceutical Companies in North America, 2020-2030 (USD Billion)
Figure 13.18 Next Generation Sequencing Market for Other Users in North America, 2020-2030 (USD Billion)
Figure 13.19 Next Generation Sequencing Market in Europe, 2020-2030 (USD Billion)
Figure 13.20 Next Generation Sequencing Market in Europe: Distribution by Application Area, 2020-2030 (USD Billion)
Figure 13.21 Next Generation Sequencing Market for Diagnostics in Europe, 2020-2030 (USD Billion)
Figure 13.22 Next Generation Sequencing Market for Drug Discovery in Europe, 2020-2030 (USD Billion)
Figure 13.23 Next Generation Sequencing Market for Precision Medicine in Europe, 2020-2030 (USD Billion)
Figure 13.24 Next Generation Sequencing Market in for Other Application Areas in Europe, 2020-2030 (USD Billion)
Figure 13.25 Next Generation Sequencing Market in Europe: Distribution by End Users, 2020- 2030 (USD Billion)
Figure 13.26 Next Generation Sequencing Market for Hospitals and Clinics in Europe, 2020- 2030 (USD Billion)
Figure 13.27 Next Generation Sequencing Market for Academic and Research Institutes in Europe, 2020-2030 (USD Billion)
Figure 13.28 Next Generation Sequencing Market for Pharmaceutical Companies in Europe, 2020-2030 (USD Billion)
Figure 13.29 Next Generation Sequencing Market for Other Users in Europe, 2020-2030 (USD Billion)
Figure 13.30 Next Generation Sequencing Market in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.31 Next Generation Sequencing Market in Asia-Pacific: Distribution by Application Area, 2020-2030 (USD Billion)
Figure 13.32 Next Generation Sequencing Market for Diagnostics in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.33 Next Generation Sequencing Market for Drug Discovery in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.34 Next Generation Sequencing Market for Precision Medicine in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.35 Next Generation Sequencing Market for Other Application Areas in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.36 Next Generation Sequencing Market in Asia-Pacific: Distribution by End-Users 2020-2030 (USD Billion)
Figure 13.37 Next Generation Sequencing Market for Hospitals and Clinics in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.38 Next Generation Sequencing Market for Academic and Research Institutes in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.39 Next Generation Sequencing Market for Pharmaceutical Companies in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.40 Next Generation Sequencing Market for Other Users in Asia-Pacific, 2020-2030 (USD Billion)
Figure 13.41 Next Generation Sequencing Market in Rest of the World, 2020-2030 (USD Billion)
Figure 13.42 Next Generation Sequencing Market in Rest of the World: Distribution by Application Area, 2020-2030 (USD Billion)
Figure 13.43 Next Generation Sequencing Market for Diagnostics in Rest of the World, 2020-2030 (USD Billion)
Figure 13.44 Next Generation Sequencing Market for Drug Discovery in Rest of the World, 2020-2030 (USD Billion)
Figure 13.45 Next Generation Sequencing Market for Precision Medicine in Rest of the World, 2020-2030 (USD Billion)
Figure 13.46 Next Generation Sequencing Market for Other Application Areas in Rest of the World, 2020-2030 (USD Billion)
Figure 13.47 Next Generation Sequencing Market in Rest of the World: Distribution by End-Users, 2020-2030 (USD Billion)
Figure 13.48 Next Generation Sequencing Market for Hospitals and Clinics in Rest of the World, 2020-2030 (USD Billion)
Figure 13.49 Next Generation Sequencing Market for Academic and Research Institutes in Rest of the World, 2020-2030 (USD Billion)
Figure 13.50 Next Generation Sequencing Market for Pharmaceutical Companies in Rest of the World, 2020-2030 (USD Billion)
Figure 13.51 Next Generation Sequencing Market for Other Users in Rest of the World, 2020-2030 (USD Billion)

List Of Tables

Table 3.1 Comparison of Available Genome Sequencing Technologies
Table 4.1 Genome Sequencing Service Providers: List of Industry Players
Table 4.2 Genome Sequencing Service Providers (Industry Players): Information on Type of Services Offered
Table 4.3 Genome Sequencing Service Providers (Industry Players): Information on Whole Genome Sequencing Services
Table 4.4 Genome Sequencing Service Providers (Industry Players): Information on Whole Exome Sequencing Services
Table 4.5 Genome Sequencing Service Providers (Industry Players): Information on Targeted Sequencing Services
Table 4.6 Genome Sequencing Service Providers: List of Non-Industry Players
Table 4.7 Genome Sequencing Service Providers (Non-Industry Players): Information on Type of Services Offered
Table 4.8 Genome Sequencing Service Providers (Non-Industry Players): Information on Whole Genome Sequencing Services
Table 4.9 Genome Sequencing Service Providers (Non-Industry Players): Information on Whole Exome Sequencing Services
Table 4.10 Genome Sequencing Service Providers (Non-Industry Players): Information on Targeted Sequencing Services
Table 5.1 Genome Sequencing: List of Available Technologies
Table 5.2 Genome Sequencing Technologies: Additional Technology Specifications
Table 5.3 List of Genome Sequencing Technology Providers
Table 7.1 BGI: Company Snapshot
Table 7.2 BGI Genomics: Recent Developments and Future Outlook
Table 7.3 Veritas: Company Snapshot
Table 7.4 Veritas: Recent Developments and Future Outlook
Table 7.5 Novogene: Company Snapshot
Table 7.6 Novogene: Recent Developments and Future Outlook
Table 7.7 GENEWIZ: Company Snapshot
Table 7.8 GENEWIZ: Recent Developments and Future Outlook
Table 7.9 Eurofins Genomics: Company Snapshot
Table 7.10 Eurofins Genomics: Recent Developments and Future Outlook
Table 7.11 CD Genomics: Company Snapshot
Table 7.12 CD Genomics: Recent Developments and Future Outlook
Table 7.13 DNA Link: Company Snapshot
Table 7.14 DNA Link: Recent Developments and Future Outlook
Table 7.15 Applied Biological Materials: Company Snapshot
Table 7.16 Applied Biological Materials: Recent Developments and Future Outlook
Table 7.17 Admera Health: Company Snapshot
Table 7.18 Admera Health: Recent Developments and Future Outlook
Table 7.19 Gene by Gene: Company Snapshot
Table 7.20 Gene by Gene: Recent Developments and Future Outlook
Table 7.21 Xcerlis Labs: Company Snapshot
Table 7.22 Xcerlis Labs: Recent Developments and Future Outlook
Table 7.23 Fulgent Genetics: Company Snapshot
Table 7.24 Fulgent Genetics: Recent Developments and Future Outlook
Table 7.25 Omega Biosciences: Company Snapshot
Table 7.26 Omega Biosciences: Recent Developments and Future Outlook
Table 7.27 Med-Genome: Company Snapshot
Table 7.28 Med-Genome: Recent Developments and Future Outlook
Table 7.29 Psomagen: Company Snapshot
Table 7.30 Psomagen: Recent Developments and Future Outlook
Table 8.1 Illumina: Recent Developments and Future Outlook
Table 8.2 Oxford Nanopore Technologies: Recent Developments and Future Outlook
Table 8.3 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 9.1 Patent Portfolio: CPC Symbols
Table 9.2 Patent Portfolio: Most Popular CPC Symbols
Table 9.3 Patent Portfolio: List of Top 10 CPC Symbols
Table 9.4 Patent Valuation Analysis: Categorization based on Weighted Valuation Scores
Table 9.5 Patent Portfolio: List of Relatively Higher Value Patents
Table 12.1 Genome Sequencing: List of Government Sponsored Initiatives
Table 12.2 Government Sponsored Initiatives: Information on Research Objectives
Table 12.3 Government Sponsored Initiatives: Additional Details
Table 12.4 Government Sponsored Initiatives: Information on Region-Specific Data Accessibility
Table 15.1 Genome Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
Table 15.2 Genome Sequencing Service Providers (Industry Players): Distribution by Company Size
Table 15.3 Genome Sequencing Service Providers (Industry Players): Distribution by Geography
Table 15.4 Genome Sequencing Service Providers (Industry Players): Distribution by Type of Services Offered
Table 15.5 Whole Genome Sequencing Services (Industry Players): Distribution by Technology Used
Table 15.6 Whole Exome Sequencing Services (Industry Players): Distribution by Technology Used
Table 15.7 Targeted Sequencing Services (Industry Players): Distribution by Technology Used
Table 15.8 Genome Sequencing Service Providers (Non-Industry Players): Distribution by Year of Establishment
Table 15.9 Genome Sequencing Service Providers (Non-Industry Players): Distribution by Geography
Table 15.10 Genome Sequencing Service Providers (Non-Industry Players): Distribution by Type of Services Offered
Table 15.11 Whole Genome Sequencing Services (Non-Industry Players): Distribution by Technology Used
Table 15.12 Whole Exome Sequencing Services (Non-Industry Players): Distribution by Technology Used
Table 15.13 Targeted Sequencing Services (Non-Industry Players): Distribution by Technology Used
Table 15.14 Genome Sequencing Technologies: Distribution by Type of Application
Table 15.15 Genome Sequencing Technologies: Distribution by Maximum Sequencing Output
Table 15.16 Genome Sequencing Technologies: Distribution by Maximum Reads per Run
Table 15.17 Genome Sequencing Technologies: Distribution by Sequencing Technique
Table 15.18 Genome Sequencing Technology Providers: Distribution by Year of Establishment
Table 15.19 Genome Sequencing Technology Providers: Distribution by Company Size
Table 15.20 Genome Sequencing Technology Providers: Distribution by Geography
Table 15.21 Illumina: Annual Revenues, 2013- Q32020 (USD Million)
Table 15.22 Thermo Fisher Scientific: Annual Revenues, 2013-Q32020 (USD Million)
Table 15.23 Patent Portfolio: Distribution by Type of Patent
Table 15.24 Patent Portfolio: Cumulative Distribution by Publication Year
Table 15.25 Patent Portfolio: Distribution by Geographical Region
Table 15.26 Patent Portfolio: Distribution by CPC Symbols
Table 15.27 Leading Players: Distribution by Size of Patent Portfolio
Table 15.28 Patent Portfolio: Benchmarking by International Patents
Table 15.29 Patent Portfolio: Distribution by Geography and Type of Patent
Table 15.30 Patent Portfolio: Distribution by Patent Age
Table 15.31 Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Trial Registration Year
Table 15.32 Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
Table 15.33 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Study Start Year
Table 15.34 Clinical Trial Analysis: Distribution by Type of Sponsors / Collaborators
Table 15.35 Clinical Trial Analysis: Distribution by Trial Status
Table 15.36 Clinical Trial Analysis: Distribution by Type of Study Design
Table 15.37 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 15.38 Clinical Trial Analysis: Distribution by Type of Application
Table 15.39 Clinical Trial Analysis: Distribution by Target Therapeutic Area and Type of Application
Table 15.40 Big Pharma Initiatives: Distribution by Type of Initiative
Table 15.41 Big Pharma Initiatives: Distribution by Type of Collaboration
Table 15.42 Big Pharma Initiatives: Distribution by Focus Area
Table 15.43 Leading Players: Distribution by Number of Initiatives
Table 15.44 Government Sponsored Initiatives: Distribution by Study Status
Table 15.45 Government Sponsored Initiatives: Distribution by Study Start Year
Table 15.46 Government Sponsored Initiatives: Distribution by Geographical Scope
Table 15.47 World Map Analysis of National Initiatives by Geographical Location, Year and Number of Genomes Sequenced
Table 15.48 Government Sponsored Initiatives: Distribution by Research Objective
Table 15.49 Government Sponsored Initiatives: Distribution by Focus Area
Table 15.50 Government Sponsored Initiatives: Distribution by Type of Players
Table 15.51 Government Sponsored Initiatives: Distribution by Type of Investors
Table 15.52 Overall Next Generation Sequencing Market, 2020-2030 (USD Billion)
Table 15.53 Next Generation Sequencing Market: Distribution by Key Market Segments, 2020-2030 (USD Billion)
Table 15.54 Genome Sequencing Products Market: Distribution by Type of Technology, 2020 and 2030 (USD Billion)
Table 15.55 Genome Sequencing Services Market: Distribution by Type of Service, 2020 and 2030 (USD Billion)
Table 15.56 Next Generation Sequencing Market: Distribution by Application Area, 2020 and 2030 (USD Billion)
Table 15.57 Next Generation Sequencing Market: Distribution by End-Users, 2020 and 2030 (USD Billion)
Table 15.58 Next Generation Sequencing Market: Distribution by Geographical Regions, 2020 and 2030 (USD Billion)
Table 15.59 Next Generation Sequencing Market in North America, 2020-2030 (USD Billion)
Table 15.60 Next Generation Sequencing Market in North America: Distribution by Application Area, 2020-2030 (USD Billion)
Table 15.61 Next Generation Sequencing Market for Diagnostics in North America, 2020-2030 (USD Billion)
Table 15.62 Next Generation Sequencing Market for Drug Discovery in North America, 2020-2030 (USD Billion)
Table 15.63 Next Generation Sequencing Market in for Precision Medicine in North America, 2020-2030 (USD Billion)
Table 15.64 Next Generation Sequencing Market in for Other Application Areas in North America, 2020-2030 (USD Billion)
Table 15.65 Next Generation Sequencing Market in North America: Distribution by End-Users, 2020-2030 (USD Billion)
Table 15.66 Next Generation Sequencing Market for Hospitals and Clinics in North America, 2020-2030 (USD Billion)
Table 15.67 Next Generation Sequencing Market for Academic and Research Institutes in North America, 2020-2030 (USD Billion)
Table 15.68 Next Generation Sequencing Market for Pharmaceutical Companies in North America, 2020-2030 (USD Billion)
Table 15.69 Next Generation Sequencing Market for Other Users in North America, 2020-2030 (USD Billion)
Table 15.70 Next Generation Sequencing Market in Europe, 2020-2030 (USD Billion)
Table 15.71 Next Generation Sequencing Market in Europe: Distribution by Application Area, 2020-2030 (USD Billion)
Table 15.72 Next Generation Sequencing Market for Diagnostics in Europe, 2020-2030 (USD Billion)
Table 15.73 Next Generation Sequencing Market for Drug Discovery in Europe, 2020-2030 (USD Billion)
Table 15.74 Next Generation Sequencing Market for Precision Medicine in Europe, 2020-2030 (USD Billion)
Table 15.75 Next Generation Sequencing Market in for Other Application Areas in Europe, 2020-2030 (USD Billion)
Table 15.76 Next Generation Sequencing Market in Europe: Distribution by End Users, 2020- 2030 (USD Billion)
Table 15.77 Next Generation Sequencing Market for Hospitals and Clinics in Europe, 2020- 2030 (USD Billion)
Table 15.78 Next Generation Sequencing Market for Academic and Research Institutes in Europe, 2020-2030 (USD Billion)
Table 15.79 Next Generation Sequencing Market for Pharmaceutical Companies in Europe, 2020-2030 (USD Billion)
Table 15.80 Next Generation Sequencing Market for Other Users in Europe, 2020-2030 (USD Billion)
Table 15.81 Next Generation Sequencing Market in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.82 Next Generation Sequencing Market in Asia-Pacific: Distribution by Application Area, 2020-2030 (USD Billion)
Table 15.83 Next Generation Sequencing Market for Diagnostics in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.84 Next Generation Sequencing Market for Drug Discovery in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.85 Next Generation Sequencing Market for Precision Medicine in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.86 Next Generation Sequencing Market for Other Application Areas in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.87 Next Generation Sequencing Market in Asia-Pacific: Distribution by End-Users 2020-2030 (USD Billion)
Table 15.88 Next Generation Sequencing Market for Hospitals and Clinics in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.89 Next Generation Sequencing Market for Academic and Research Institutes in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.90 Next Generation Sequencing Market for Pharmaceutical Companies in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.91 Next Generation Sequencing Market for Other Users in Asia-Pacific, 2020-2030 (USD Billion)
Table 15.92 Next Generation Sequencing Market in Rest of the World, 2020-2030 (USD Billion)
Table 15.93 Next Generation Sequencing Market in Rest of the World: Distribution by Application Area, 2020-2030 (USD Billion)
Table 15.94 Next Generation Sequencing Market for Diagnostics in Rest of the World, 2020-2030 (USD Billion)
Table 15.95 Next Generation Sequencing Market for Drug Discovery in Rest of the World, 2020-2030 (USD Billion)
Table 15.96 Next Generation Sequencing Market for Precision Medicine in Rest of the World, 2020-2030 (USD Billion)
Table 15.97 Next Generation Sequencing Market for Other Application Areas in Rest of the World, 2020-2030 (USD Billion)
Table 15.98 Next Generation Sequencing Market in Rest of the World: Distribution by End-Users, 2020-2030 (USD Billion)
Table 15.99 Next Generation Sequencing Market for Hospitals and Clinics in Rest of the World, 2020-2030 (USD Billion)
Table 15.100 Next Generation Sequencing Market for Academic and Research Institutes in Rest of the World, 2020-2030 (USD Billion)
Table 15.101 Next Generation Sequencing Market for Pharmaceutical Companies in Rest of the World, 2020-2030 (USD Billion)
Table 15.102 Next Generation Sequencing Market for Other Users in Rest of the World, 2020-2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 1st base
  2. 23andMe
  3. AbbVie
  4. AbCellera
  5. Active Motif
  6. Activiomics
  7. Adaltis
  8. Admera Health
  9. Agiomix
  10. AgriGenome Labs 
  11. AKESOgen
  12. Almac Group
  13. American Association for Cancer Research 
  14. Amgen
  15. Annoroad Gene Technology
  16. ANTISEL
  17. Applied Biological Materials
  18. Arizona Genomics Institute 
  19. Arizona Technology Enterprises
  20. Arthritis Research UK
  21. ARUP Laboratories
  22. Asper Biogene
  23. AstraZeneca
  24. Asuragen
  25. Auragen
  26. Australian Genome Research Facility 
  27. BaseClear 
  28. Bayer
  29. BGI
  30. Bio Basic
  31. BioAnalytical Services Laboratory (University of Maryland)
  32. BIOFIDAL
  33. Bionano Genomics
  34. Biosearch Technologies
  35. Biotechnology Center (University of Wisconsin)
  36. Boehringer Ingelheim
  37. Bristol-Myers Squibb
  38. Broad Institute
  39. C-Camp (Next Generation Genomics facility)
  40. CD Genomics
  41. CeGaT
  42. Celsius Therapeutics
  43. CEN4GEN
  44. Center for Applied Genomics (Children's Hospital of Philadelphia)
  45. Center for biomedical research Support (University of Texas)
  46. Centogene
  47. Centre for Genome Biology (University of Bologna)
  48. Centre for Genomic Research (University of Liverpool)
  49. Chromous
  50. Cold Spring Harbor Laboratory Next Generation Genomics Core 
  51. Columbia Genome Center
  52. Columbia University
  53. Complete Genomics
  54. Computomics
  55. Contextual Genomics
  56. CosmosID
  57. Daiichi Sankyo
  58. Dante Labs
  59. DBS Genomics (Durham University)
  60. DC3 Therapeutics
  61. De Novo Genomics
  62. deCODE genetics
  63. DiaCarta
  64. Diagnomics
  65. Diversigen
  66. DNA Genotek
  67. DNA Link
  68. DNA Sequencing & Genotyping Center Delaware Biotechnology Institute 
  69. DNA Sequencing and Gene Analysis Center (University of Washington)
  70. DNA Sequencing Center (Brigham Young University)
  71. DNAnexus 
  72. DNAVision
  73. Dow Agrosciences
  74. Earlham Institute 
  75. Edinburgh Genomics
  76. Epigenomics Core
  77. Eurofins Genomics
  78. Fasteris
  79. Ferring Pharmaceuticals
  80. Firalis
  81. Five Prime Therapeutics
  82. Foundation Medicine
  83. Frasergen Bioinformatics 
  84. Fulgent Genetics
  85. Full Genomes
  86. Functional Genomics Center Zurich (University of Zürich)
  87. GenapSys
  88. Gencove
  89. Gene by Gene
  90. Genentech
  91. GenePlanet
  92. GeneTech
  93. GENEWIZ
  94. Genia Technologies
  95. Genialis
  96. Genome
  97. Genome Quebec Innovation Centre
  98. Genome Technology Access Center (University of Washington)
  99. GenomeFan
  100. GenomeScan
  101. GenomeStream
  102. Genomics and Sequencing Center (University of Rhode Island)
  103. Genomics Evidence Neoplasia Information Exchange
  104. Genomics Medicine Ireland
  105. Genomics Personalized Health
  106. Genomics Sequencing Service Center (Stanford Medicine)
  107. Genomix4Life
  108. Genoptix
  109. Genosity
  110. Genotypic Technology 
  111. Gilead Sciences
  112. GlaxoSmithKline
  113. GRAIL
  114. Halozyme Therapeutics
  115. Harvard University
  116. Health Wadsworth Center
  117. Healthcare and Bioscience iNet
  118. HistoGenetics
  119. Horizon Discovery
  120. HudsonAlpha Genome Sequencing Center
  121. Human Genome Sciences
  122. Human Longevity
  123. Icahn Institute for Data Science and Genomic Technology
  124. Illumina
  125. Inotrem
  126. Institute for Food Safety and Health (Illinois Institute of Technology)
  127. Integrative Genomics Core (City of Hope)
  128. International Wheat Genome Sequencing Consortium
  129. Jan-Willem de Gier (Stockholm University)
  130. Johns Hopkins University
  131. Johnson and Johnson
  132. Jouvene
  133. Kapa Biosystems
  134. Kazusa DNA Research Institute
  135. KCCG Sequencing Laboratory (Garvan Institute of Medical Research)
  136. LC Sciences
  137. Loop Genomics
  138. Loxo Oncology
  139. Lucigen
  140. Macrogen
  141. Maryland Genomics
  142. Massachusetts General Hospital
  143. Massachusetts Institute of Technology
  144. Massey Genome Service (Massey University)
  145. Max Planck-Genome-centre Cologne
  146. McDonnell Genome Institute (Washington University)
  147. McGill University 
  148. MedGenome
  149. MedImmune (a subsidiary of AstraZeneca)
  150. Medivir
  151. Merck 
  152. MGI Tech
  153. Microba
  154. Microgenomics
  155. Microsynth
  156. MNG Laboratories (Medical Neurogenetics)
  157. MOgene
  158. MolDiag Solutions
  159. Molecular Biology and Genomics Core (Washington State University) 
  160. MongoDB
  161. MRC Human Genetics Unit (University of Edinburgh)
  162. myGenomics
  163. Myriad Genetics
  164. Nabsys
  165. National Genomics Infrastructure (University of Uppsala)
  166. National Instrumentation Center for Environmental Management
  167. Nebula Genomics
  168. New York Genome Center
  169. Next Generation Sequencing Core (Oklahoma Medical Research Foundation)
  170. Next Generation Sequencing Facility (University of Leeds)
  171. Novartis
  172. Novogene 
  173. Nucleics
  174. Nucleome
  175. Ocean Genome Legacy
  176. Okairos and Conatus
  177. Omega Bioservices
  178. Oncimmune
  179. OpGen
  180. Otogenetics
  181. Oxford Genomics Centre
  182. Oxford Nanopore Technologies
  183. Oxford University Consortium
  184. Pacific Biosciences
  185. Partners HealthCare Personalized Medicine
  186. PerkinElmer Genomics
  187. Pfizer
  188. Phalanx Biotech
  189. Phoenix Molecular Designs 
  190. Pierre Fabre
  191. Protein and Nucleic Acid Facility
  192. Psomagen
  193. Q2 Solutions
  194. QIAGEN
  195. Quick Biology
  196. Rady Children's Institute for Genomic Medicine
  197. Ramaciotti Centre for Genomics (UNSW Sydney)
  198. RAPiD Genomics
  199. REPROCELL
  200. Roche
  201. RTLGenomics
  202. San Diego Supercomputer Center
  203. Sanofi 
  204. Scripps Translational Science Institute
  205. Second Genome
  206. SeqLL
  207. SeqMatic
  208. Sequencing Center
  209. Shanghai OE Biotech
  210. Source BioScience
  211. SRM 
  212. Stanford University
  213. StarSEQ
  214. Stratos Genomics
  215. Synbio Technologies
  216. Technology Center for Genomics & Bioinformatics (UCLA)
  217. Texas A&M AgriLife
  218. Theragen Etex Bio
  219. Thermo Fisher Scientific
  220. Toldot Genetics
  221. UCB
  222. UCLA Clinical Genomics Center
  223. UK's Medical Research Foundation
  224. United Therapeutics
  225. University of California
  226. University of Leicester
  227. University of London 
  228. University of Minnesota Genomics Center
  229. University of Nottingham
  230. University of Utah Health
  231. Veritas
  232. Waksman Institute of Microbiology (Rutgers University)
  233. Wellcome Sanger Institute
  234. WuXi NextCODE
  235. Xcelris Labs
  236. Yaazh Xenomics
  237. Yale Center for Genome Analysis (Yale School of Medicine)
  238. Yikon Genomics

Segmentation

The USD 19 billion (by 2030) financial opportunity within the next generation sequencing market has been analyzed across the following segments:

  • Type of Offering
    • Products
    • Services
  • Type of sequencing technology used
    • Sequencing by synthesis (SBS)
    • Ion semiconductor sequencing
    • Single Molecule, Real-Time (SMRT) sequencing
    • Nanopore sequencing
    • Others
  • Key application areas
    • Diagnostics
    • Drug discovery and personalized medicine
    • Reproductive health
  • End-users
    • Academic and research institutes
    • Hospitals and clinics
    • Pharmaceutical companies
    • Others

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com